Paul Revill

Personal Details

First Name:	Paul
Middle Name:	Andrew
Last Name:	Revill
Suffix:
RePEc Short-ID:	pre353
	[This author has chosen not to make the email address public]

Affiliation

Centre for Health Economics
Department of Economics and Related Studies
University of York

York, United Kingdom
https://www.york.ac.uk/che/
RePEc:edi:chyoruk (more details at EDIRC)

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:

1. Paul Revill & Simon Walker & Jason Madan & Andrea Ciaranello & Takondwa Mwase & Diana M Gibb & Karl Claxton & Mark J Sculpher, 2014. "Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: Are current international norms fit for purpose?," Working Papers 098cherp, Centre for Health Economics, University of York.

   Mentioned in:

   1. Opportunity costs, marginal productivity, and cost-effectiveness thresholds: what are they and how are they related?
      by Rita Faria, Jessica Ochalek, jameslomas88 in The Academic Health Economists' Blog on 2020-09-23 06:00:00

Working papers

1. James Love-Koh & Susan Griffin & Edward Kataika & Paul Revill & Sibusiso Sibandze & Simon Walker, 2019. "Incorporating concerns for equity into health resource allocation. A guide for practitioners," Working Papers 160cherp, Centre for Health Economics, University of York.

   Cited by:

   1. James Love-Koh & Susan Griffin & Edward Kataika & Paul Revill & Sibusiso Sibandze & Simon Walker & Jessica Ochalek & Mark Sculpher & Matthias Arnold, 2019. "Economic analysis for health benefits package design," Working Papers 165cherp, Centre for Health Economics, University of York.

2. Jessica Ochalek & Karl Claxton & Paul Revill & Mark Sculpher & Alexandra Rollinger, 2016. "Supporting the development of an essential health package: principles and initial assessment for Malawi," Working Papers 136cherp, Centre for Health Economics, University of York.

   Cited by:

   1. Caitlin M. Walsh & Takondwa Mwase & Manuela De Allegri, 2020. "How actors, processes, context and evidence influenced the development of Malawi's Health Sector Strategic Plan II," International Journal of Health Planning and Management, Wiley Blackwell, vol. 35(6), pages 1571-1592, November.
   2. Praveen Thokala & Jessica Ochalek & Ashley A. Leech & Thaison Tong, 2018. "Cost-Effectiveness Thresholds: the Past, the Present and the Future," PharmacoEconomics, Springer, vol. 36(5), pages 509-522, May.
   3. Gesine Meyer-Rath & Craig van Rensburg & Bruce Larson & Lise Jamieson & Sydney Rosen, 2017. "Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-9, October.

3. Beth Woods & Paul Revill & Mark Sculpher & Karl Claxton, 2015. "Country-level cost-effectiveness thresholds: initial estimates and the need for further research," Working Papers 109cherp, Centre for Health Economics, University of York.

   Cited by:

   1. Anita J. Brogan & Sandra E. Talbird & Ashley E. Davis & Elizabeth M. La & Princy N. Kumar, 2021. "The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States," PharmacoEconomics, Springer, vol. 39(4), pages 421-432, April.
   2. Beth Woods & Claire Rothery & Paul Revill & Timothy Hallett & Andrew Phillips & Karl Claxton., 2018. "Setting research priorities in Global Health:Appraising the value of evidence generation activities to support decision-making in health care," Working Papers 155cherp, Centre for Health Economics, University of York.
   3. Dominic Byrne & Do Won Kwak & Kam Ki Tang & Myra Yazbeck, 2020. "Spillover Effects of Retirement: does health vulnerability matter?," Discussion Papers Series 620, School of Economics, University of Queensland, Australia.
      • Byrne, Dominic & Kwak, Do Won & Tang, Kam Ki & Yazbeck, Myra, 2023. "Spillover effects of retirement: Does health vulnerability matter?," Economics & Human Biology, Elsevier, vol. 48(C).
      • Dominic Byrne & Do Won Kwak & Kam Ki Tang & Myra Yazbeck, 2021. "Spillover Effects of Retirement: does health vulnerability matter?," Discussion Papers Series 643, School of Economics, University of Queensland, Australia.
   4. Niek Stadhouders & Xander Koolman & Christel van Dijk & Patrick Jeurissen & Eddy Adang, 2019. "The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function," Health Economics, John Wiley & Sons, Ltd., vol. 28(11), pages 1331-1344, November.
   5. Halimatou Diawara & Patrick Walker & Matt Cairns & Laura C Steinhardt & Fatou Diawara & Beh Kamate & Laetitia Duval & Elisa Sicuri & Issaka Sagara & Aboubacar Sadou & Jules Mihigo & Erin Eckert & Alas, 2021. "Cost-effectiveness of district-wide seasonal malaria chemoprevention when implemented through routine malaria control programme in Kita, Mali using fixed point distribution," Université Paris1 Panthéon-Sorbonne (Post-Print and Working Papers) hal-03184961, HAL.
      • Halimatou Diawara & Patrick Walker & Matt Cairns & Laura C Steinhardt & Fatou Diawara & Beh Kamate & Laetitia Duval & Elisa Sicuri & Issaka Sagara & Aboubacar Sadou & Jules Mihigo & Erin Eckert & Alas, 2021. "Cost-effectiveness of district-wide seasonal malaria chemoprevention when implemented through routine malaria control programme in Kita, Mali using fixed point distribution," Post-Print hal-03184961, HAL.
   6. Laura Catherine Edney & Hossein Haji Ali Afzali & Terence Chai Cheng & Jonathan Karnon, 2018. "Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System," PharmacoEconomics, Springer, vol. 36(2), pages 239-252, February.
   7. Jan-Walter De Neve & Rija L Andriantavison & Kevin Croke & Johannes Krisam & Voahirana H Rajoela & Rary A Rakotoarivony & Valérie Rambeloson & Linda Schultz & Jumana Qamruddin & Stéphane Verguet, 2018. "Health, financial, and education gains of investing in preventive chemotherapy for schistosomiasis, soil-transmitted helminthiases, and lymphatic filariasis in Madagascar: A modeling study," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 12(12), pages 1-17, December.
   8. Anthony J Culyer, 2015. "Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use," Working Papers 121cherp, Centre for Health Economics, University of York.
      • Culyer, Anthony J., 2016. "Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use," Health Economics, Policy and Law, Cambridge University Press, vol. 11(4), pages 415-432, October.
   9. Jessica Ochalek & Haiyin Wang & Yuanyuan Gu & James Lomas & Henry Cutler & Chunlin Jin, 2020. "Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach," PharmacoEconomics, Springer, vol. 38(12), pages 1319-1331, December.
   10. James O’Mahony & Diarmuid Coughlan, 2016. "The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System?," PharmacoEconomics, Springer, vol. 34(1), pages 5-11, January.
   11. Caitlin M Dugdale & Tamsin K Phillips & Landon Myer & Emily P Hyle & Kirsty Brittain & Kenneth A Freedberg & Lucy Cunnama & Rochelle P Walensky & Allison Zerbe & Milton C Weinstein & Elaine J Abrams &, 2019. "Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa," PLOS ONE, Public Library of Science, vol. 14(11), pages 1-18, November.
   12. Jessica Ochalek & Karl Claxton & Paul Revill & Mark Sculpher & Alexandra Rollinger, 2016. "Supporting the development of an essential health package: principles and initial assessment for Malawi," Working Papers 136cherp, Centre for Health Economics, University of York.
   13. Markiewicz Olimpia, 2021. "Value of Life Year and Cost-Effectiveness Thresholds: The Case of Poland," Central European Economic Journal, Sciendo, vol. 8(55), pages 256-268, January.
   14. Peter J. Neumann & David D. Kim & Thomas A. Trikalinos & Mark J. Sculpher & Joshua A. Salomon & Lisa A. Prosser & Douglas K. Owens & David O. Meltzer & Karen M. Kuntz & Murray Krahn & David Feeny & An, 2018. "Future Directions for Cost-effectiveness Analyses in Health and Medicine," Medical Decision Making, , vol. 38(7), pages 767-777, October.
   15. Paul Revill & Simon Walker & Valentina Cambiano & Andrew Phillips & Mark J Sculpher, 2018. "Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-13, January.
   16. Samuel N. Frempong & Andrew J. Sutton & Clare Davenport & Pelham Barton, 2020. "Early Economic Evaluation to Identify the Necessary Test Characteristics of a New Typhoid Test to be Cost Effective in Ghana," PharmacoEconomics - Open, Springer, vol. 4(1), pages 143-157, March.
   17. Laia Cirera & Beatriz Galatas & Sergi Alonso & Krijn Paaijmans & Miler Mamuquele & Helena Martí-Soler & Caterina Guinovart & Humberto Munguambe & Fabião Luis & Hoticha Nhantumbo & Júlia Montañà & Quiq, 2020. "Moving towards malaria elimination in southern Mozambique: Cost and cost-effectiveness of mass drug administration combined with intensified malaria control," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-17, July.
   18. Claxton, Karl & Asaria, Miqdad & Chansa, Collins & Jamison, Julian & Lomas, James & Ochalek, Jessica & Paulden, Mike, 2019. "Accounting for timing when assessing health-related policies," LSE Research Online Documents on Economics 100408, London School of Economics and Political Science, LSE Library.
       • Claxton, Karl & Asaria, Miqdad & Chansa, Collins & Jamison, Julian & Lomas, James & Ochalek, Jessica & Paulden, Mike, 2019. "Accounting for Timing when Assessing Health-Related Policies," Journal of Benefit-Cost Analysis, Cambridge University Press, vol. 10(S1), pages 73-105, April.
   19. Aidan Hollis, 2016. "Sustainable Financing of Innovative Therapies: A Review of Approaches," PharmacoEconomics, Springer, vol. 34(10), pages 971-980, October.
   20. Sebastian Himmler & Jannis Stöckel & Job van Exel & Werner Brouwer, 2020. "The Value of Health - Empirical Issues when Estimating the Monetary Value of a QALY Based on Well-Being," SOEPpapers on Multidisciplinary Panel Data Research 1101, DIW Berlin, The German Socio-Economic Panel (SOEP).
   21. Charles E Okafor & Obinna I Ekwunife, 2017. "Cost-effectiveness analysis of diarrhoea management approaches in Nigeria: A decision analytical model," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 11(12), pages 1-14, December.
   22. Yared Belete Belay & Eskinder Eshetu Ali & Karen Y. Chung & Gebremedhin Beedemariam Gebretekle & Beate Sander, 2021. "Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia," PharmacoEconomics - Open, Springer, vol. 5(4), pages 655-664, December.
   23. Maciel, Roberto Rodrigues Bandeira Tosta & Chiavegato, Luciana Dias & Marin, Luz Stella & Portella, Daniel Deivson Alves & de Souza, Marcio Costa & Camelier, Fernanda Warken Rosa & Padula, Rosimeire S, 2019. "Development of an e-health education program at the workplace using formative research – Technologies for improving quality of life," Evaluation and Program Planning, Elsevier, vol. 73(C), pages 129-137.
   24. William V. Padula & Hui-Han Chen & Charles E. Phelps, 2021. "Is the Choice of Cost-Effectiveness Threshold in Cost-Utility Analysis Endogenous to the Resulting Value of Technology? A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 19(2), pages 155-162, March.
   25. Elisabeth PAUL & Fabienne FECHER & Céline DEVILLE & Youssoupha NDIAYE & Farba Lamine SALL & N’koué EmmanuelSAMBIÉNI & Remo MELONI & Denis PORIGNON, 2020. "Long Way to Universal Health Coverage (UHC): Are Policy Dialogue Processes Appropriate to Negotiate Trade-Offs in Africa? The Cases of Benin and Senegal," CIRIEC Working Papers 2005, CIRIEC - Université de Liège.
   26. Praveen Thokala & Jessica Ochalek & Ashley A. Leech & Thaison Tong, 2018. "Cost-Effectiveness Thresholds: the Past, the Present and the Future," PharmacoEconomics, Springer, vol. 36(5), pages 509-522, May.
   27. Krishna P. Reddy & Kieran P. Fitzmaurice & Justine A. Scott & Guy Harling & Richard J. Lessells & Christopher Panella & Fatma M. Shebl & Kenneth A. Freedberg & Mark J. Siedner, 2021. "Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa," Nature Communications, Nature, vol. 12(1), pages 1-10, December.
   28. Marwân-Al-Qays Bousmah & Marie Libérée Nishimwe & Tamara Tovar-Sanchez & Martial Lantche Wandji & Mireille Mpoudi-Etame & Gwenaëlle Maradan & Pierrette Omgba Bassega & Marie Varloteaux & Alice Montoyo, 2021. "Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)," Post-Print hal-03174666, HAL.
       • Marwân-al-Qays Bousmah & Marie Libérée Nishimwe & Tamara Tovar-Sanchez & Martial Lantche Wandji & Mireille Mpoudi-Etame & Gwenaëlle Maradan & Pierrette Omgba Bassega & Marie Varloteaux & Alice Montoyo, 2021. "Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)," PharmacoEconomics, Springer, vol. 39(3), pages 331-343, March.
   29. Morton, Alec & Arulselvan, Ashwin & Thomas, Ranjeeta, 2018. "Allocation rules for global donors," LSE Research Online Documents on Economics 101210, London School of Economics and Political Science, LSE Library.
   30. Amani Thomas Mori & Ole Frithjof Norheim & Bjarne Robberstad, 2016. "Budget Impact Analysis of Using Dihydroartemisinin–Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania," PharmacoEconomics, Springer, vol. 34(3), pages 303-314, March.
   31. Amani Mori & Ole Norheim & Bjarne Robberstad, 2016. "Budget Impact Analysis of Using Dihydroartemisinin–Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania," PharmacoEconomics, Springer, vol. 34(3), pages 303-314, March.
   32. James Love-Koh & Susan Griffin & Edward Kataika & Paul Revill & Sibusiso Sibandze & Simon Walker & Jessica Ochalek & Mark Sculpher & Matthias Arnold, 2019. "Economic analysis for health benefits package design," Working Papers 165cherp, Centre for Health Economics, University of York.
   33. Anuj Tiwari & David J Blok & Mohammad Arif & Jan Hendrik Richardus, 2020. "Leprosy post-exposure prophylaxis in the Indian health system: A cost-effectiveness analysis," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 14(8), pages 1-12, August.
   34. Morton, Alec & Arulselvan, Ashwin & Thomas, Ranjeeta, 2018. "Allocation rules for global donors," Journal of Health Economics, Elsevier, vol. 58(C), pages 67-75.
   35. Torbjørn Wisløff & Richard White & Olav Dalgard & Ellen J. Amundsen & Hinta Meijerink & Astrid Louise Løvlie & Hilde Kløvstad, 2018. "Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway," PharmacoEconomics, Springer, vol. 36(5), pages 591-601, May.
   36. Max J. Korman & Kjetil Retterstøl & Ivar Sønbø Kristiansen & Torbjørn Wisløff, 2018. "Are PCSK9 Inhibitors Cost Effective?," PharmacoEconomics, Springer, vol. 36(9), pages 1031-1041, September.
   37. Eda Ustaoglu & Brendan Williams, 2020. "Cost-Benefit Evaluation Tools on the Impacts of Transport Infrastructure Projects on Urban Form and Development," Chapters, in: Vito Bobek (ed.), Smart Urban Development, IntechOpen.
   38. Charles Ebuka Okafor, 2021. "Introducing Rotavirus Vaccination in Nigeria: Economic Evaluation and Implications," PharmacoEconomics - Open, Springer, vol. 5(3), pages 545-557, September.
   39. Pieter van Baal & Meg Perry‐Duxbury & Pieter Bakx & Matthijs Versteegh & Eddy van Doorslaer & Werner Brouwer, 2019. "A cost‐effectiveness threshold based on the marginal returns of cardiovascular hospital spending," Health Economics, John Wiley & Sons, Ltd., vol. 28(1), pages 87-100, January.
   40. Philippe Grandjean & Martine Bellanger, 2017. "Calculation of the disease burden associated with environmental chemical exposures: application of toxicological information in health economic estimation," Post-Print hal-02464775, HAL.

4. Paul Revill & Simon Walker & Jason Madan & Andrea Ciaranello & Takondwa Mwase & Diana M Gibb & Karl Claxton & Mark J Sculpher, 2014. "Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: Are current international norms fit for purpose?," Working Papers 098cherp, Centre for Health Economics, University of York.

   Cited by:

   1. Ryota Nakamura & James Lomas & Karl Claxton & Farasat Bokhari & Rodrigo Moreno Serra & Marc Suhrcke, 2016. "Assessing the impact of health care expenditures on mortality using cross-country data," Working Papers 128cherp, Centre for Health Economics, University of York.
      • Ryota Nakamura & James Lomas & Karl Claxton & Farasat Bokhari & Rodrigo Moreno-Serra & Marc Suhrcke & Peter Berman, 2020. "Assessing the Impact of Health Care Expenditures on Mortality Using Cross-Country Data," World Scientific Book Chapters, in: Paul Revill & Marc Suhrcke & Rodrigo Moreno-Serra & Mark Sculpher (ed.), Global Health Economics Shaping Health Policy in Low- and Middle-Income Countries, chapter 1, pages 3-49, World Scientific Publishing Co. Pte. Ltd..
   2. Tom L. Drake & Angela Devine & Shunmay Yeung & Nicholas P. J. Day & Lisa J. White & Yoel Lubell, 2016. "Dynamic Transmission Economic Evaluation of Infectious Disease Interventions in Low‐ and Middle‐Income Countries: A Systematic Literature Review," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 124-139, February.
   3. Anthony J Culyer, 2015. "Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use," Working Papers 121cherp, Centre for Health Economics, University of York.
      • Culyer, Anthony J., 2016. "Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use," Health Economics, Policy and Law, Cambridge University Press, vol. 11(4), pages 415-432, October.
   4. Anthony J Culyer, 2015. "Efficiency, equity and equality in health and health care," Working Papers 120cherp, Centre for Health Economics, University of York.
   5. Jessica Ochalek & James Lomas & Karl Claxton, 2015. "Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data," Working Papers 122cherp, Centre for Health Economics, University of York.
   6. Jessica Ochalek & Karl Claxton & Paul Revill & Mark Sculpher & Alexandra Rollinger, 2016. "Supporting the development of an essential health package: principles and initial assessment for Malawi," Working Papers 136cherp, Centre for Health Economics, University of York.
   7. Matthew Franklin & Colin Angus & Tobias Welte & Guy Joos, 2023. "How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts," Applied Health Economics and Health Policy, Springer, vol. 21(4), pages 547-558, July.
   8. Mujaheed Shaikh & Afschin Gandjour, 2019. "Pharmaceutical expenditure and gross domestic product: Evidence of simultaneous effects using a two‐step instrumental variables strategy," Health Economics, John Wiley & Sons, Ltd., vol. 28(1), pages 101-122, January.
   9. Jessica Ochalek & Miqdad Asaria & Pei Fen Chuar & James Lomas & Sumit Mazumdar & Karl Claxton, 2019. "Assessing health opportunity costs for the Indian health care systems," Working Papers 161cherp, Centre for Health Economics, University of York.
   10. Beth Woods & Paul Revill & Mark Sculpher & Karl Claxton, 2015. "Country-level cost-effectiveness thresholds: initial estimates and the need for further research," Working Papers 109cherp, Centre for Health Economics, University of York.

Articles

1. Paul Revill & Simon Walker & Valentina Cambiano & Andrew Phillips & Mark J Sculpher, 2018. "Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-13, January.

   Cited by:

   1. James Love-Koh & Susan Griffin & Edward Kataika & Paul Revill & Sibusiso Sibandze & Simon Walker & Jessica Ochalek & Mark Sculpher & Matthias Arnold, 2019. "Economic analysis for health benefits package design," Working Papers 165cherp, Centre for Health Economics, University of York.
   2. Matthew Franklin & James Lomas & Simon Walker & Tracey Young, 2019. "An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 37(5), pages 631-643, May.

2. Ochalek, Jessica & Revill, Paul & van den Berg, Bernard, 2017. "Causal effects of HIV on employment status in low-income settings," Economics & Human Biology, Elsevier, vol. 27(PA), pages 248-260.

   Cited by:

   1. Yunjiang Yu & Zhi Chen & Shenglan Huang & Zhicheng Chen & Kailin Zhang, 2020. "What determines employment quality among people living with HIV: An empirical study in China," PLOS ONE, Public Library of Science, vol. 15(12), pages 1-12, December.
   2. Jockers, Dominik & Langlotz, Sarah & French, Declan & Bärnighausen, Till, 2021. "HIV treatment and worker absenteeism: Quasi-experimental evidence from a large-scale health program in South Africa," Journal of Health Economics, Elsevier, vol. 79(C).
   3. Bidzha, Mashudu Lucas & Ngepah, Nicholas & Greyling, Talita, 2024. "The impact of antiretroviral treatment on the relationship between HIV/AIDS and economic growth," Economic Analysis and Policy, Elsevier, vol. 81(C), pages 368-387.
   4. Giachello, Marta & Leporatti, Lucia & Levaggi, Rosella & Montefiori, Marcello, 2024. "The illness trap: The impact of disability benefits on willingness to receive HCV treatment," Economics & Human Biology, Elsevier, vol. 52(C).
   5. Beatriz Rodríguez-Sánchez & Luz María Peña-Longobardo & Juan Oliva-Moreno, 2022. "The employment situation of people living with HIV: a closer look at the effects of the 2008 economic crisis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(3), pages 485-497, April.

3. Andrew N Phillips & Valentina Cambiano & Fumiyo Nakagawa & Loveleen Bansi-Matharu & Papa Salif Sow & Peter Ehrenkranz & Deborah Ford & Owen Mugurungi & Tsitsi Apollo & Joseph Murungu & David R Bangsbe, 2016. "Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa," PLOS ONE, Public Library of Science, vol. 11(12), pages 1-20, December.

   Cited by:

   1. Juan J. DelaCruz & Christos Giannikos & Andreas Kakolyris & Robert C. Utzinger & Stephen E. Karpiak, 2021. "Cost-Effectiveness Analysis Combining Medical and Mental Health Services for Older Adults with HIV in New York City," Atlantic Economic Journal, Springer;International Atlantic Economic Society, vol. 49(1), pages 43-56, March.

4. Jason Madan & Anthony E. Ades & Malcolm Price & Kathryn Maitland & Julie Jemutai & Paul Revill & Nicky J. Welton, 2014. "Strategies for Efficient Computation of the Expected Value of Partial Perfect Information," Medical Decision Making, , vol. 34(3), pages 327-342, April.

   Cited by:

   1. Anna Heath & Ioanna Manolopoulou & Gianluca Baio, 2017. "A Review of Methods for Analysis of the Expected Value of Information," Medical Decision Making, , vol. 37(7), pages 747-758, October.
   2. Wei Fang & Zhenru Wang & Michael B. Giles & Chris H. Jackson & Nicky J. Welton & Christophe Andrieu & Howard Thom, 2022. "Multilevel and Quasi Monte Carlo Methods for the Calculation of the Expected Value of Partial Perfect Information," Medical Decision Making, , vol. 42(2), pages 168-181, February.

Chapters

1. Yevgeny Goryakin & Paul Revill & Andrew J. Mirelman & Rohan Sweeney & Jessica Ochalek & Marc Suhrcke & Peter Berman, 2020. "Public Financial Management and Health Service Delivery: A Literature Review," World Scientific Book Chapters, in: Paul Revill & Marc Suhrcke & Rodrigo Moreno-Serra & Mark Sculpher (ed.), Global Health Economics Shaping Health Policy in Low- and Middle-Income Countries, chapter 7, pages 191-215, World Scientific Publishing Co. Pte. Ltd..

   Cited by:

   1. Elisabeth Paul & N’koué Emmanuel Sambiéni & Jean-Pierre Wangbe & Fabienne Fecher & Marc Bourgeois, 2020. "Budgeting challenges on the path towards universal health coverage: the case of Benin," Health Economics Review, Springer, vol. 10(1), pages 1-8, December.
   2. Robert John Kolesar & Peter Bogetoft & Vanara Chea & Guido Erreygers & Sambo Pheakdey, 2022. "Advancing universal health coverage in the COVID-19 era: an assessment of public health services technical efficiency and applied cost allocation in Cambodia," Health Economics Review, Springer, vol. 12(1), pages 1-20, December.
      • Robert John Kolesar & Peter Bogetoft & Vanara Chea & Guido Erreygers & Sambo Pheakdey, 2021. "Advancing Universal Health Coverage in the COVID-19 Era : An Assessment of Public Health Services Technical Efficiency and Applied Cost Allocation in Cambodia," Working Papers hal-03437398, HAL.
   3. Daniel Chukwuemeka Ogbuabor & Obinna Emmanuel Onwujekwe, 2019. "Aligning public financial management system and free healthcare policies: lessons from a free maternal and child healthcare programme in Nigeria," Health Economics Review, Springer, vol. 9(1), pages 1-10, December.
   4. Elisabeth Paul & N'koué Emmanuel Sambiéni & Jean-Pierre Wangbe & Fabienne Fecher & Marc Bourgeois, 2020. "Budgeting challenges on the path towards universal health coverage: the case of Benin," ULB Institutional Repository 2013/312499, ULB -- Universite Libre de Bruxelles.

2. Paul Revill & Jessica Ochalek & James Lomas & Ryota Nakamura & Beth Woods & Alexandra Rollinger & Marc Suhrcke & Mark Sculpher & Karl Claxton & Peter Berman, 2020. "Cost-Effectiveness Thresholds: Guiding Health Care Spending for Population Health Improvement," World Scientific Book Chapters, in: Paul Revill & Marc Suhrcke & Rodrigo Moreno-Serra & Mark Sculpher (ed.), Global Health Economics Shaping Health Policy in Low- and Middle-Income Countries, chapter 3, pages 75-97, World Scientific Publishing Co. Pte. Ltd..

   Cited by:

   1. Yashika Chugh & Radha Krishan Dhiman & Madhumita Premkumar & Shankar Prinja & Gagandeep Singh Grover & Pankaj Bahuguna, 2019. "Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal cove," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-24, August.
   2. Gesine Meyer-Rath & Craig van Rensburg & Bruce Larson & Lise Jamieson & Sydney Rosen, 2017. "Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-9, October.
   3. Alexei Botchkarev, 2016. "Essential notion of the health economic evaluation: Definition," Economic Analysis Working Papers (2002-2010). Atlantic Review of Economics (2011-2016), Colexio de Economistas de A Coruña, Spain and Fundación Una Galicia Moderna, vol. 2, pages 1-1, December.

Books

1. Paul Revill & Marc Suhrcke & Rodrigo Moreno-Serra & Mark Sculpher (ed.), 2020. "Global Health Economics:Shaping Health Policy in Low- and Middle-Income Countries," World Scientific Books, World Scientific Publishing Co. Pte. Ltd., number 11045, September.

   Cited by:

   1. Dirk Steijger & Chandrima Chatterjee & Wim Groot & Milena Pavlova, 2022. "Challenges and Limitations in Distributional Cost-Effectiveness Analysis: A Systematic Literature Review," IJERPH, MDPI, vol. 20(1), pages 1-14, December.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 5 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.

1. NEP-HEA: Health Economics (4) 2014-05-24 2015-03-13 2016-10-02 2018-07-16
2. NEP-IAS: Insurance Economics (1) 2019-06-17
3. NEP-PKE: Post Keynesian Economics (1) 2014-05-24

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Paul Andrew Revill should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.